Baker McKenzie Baker McKenzie
How Can We Help?
  • Home
  • Expertise
  • Life Sciences Transactions

Life Sciences Transactions

Life Sciences Business Evolution Series: Funding Growth and the Future of Life Sciences

Life sciences companies intend to leverage new and existing sources of growth including through M&A, carve-outs, divestitures, partnerships, licensing and collaboration agreements as well as avenues tied to corporate PPAs and green financing. Find out about these trajectories as well as continued VC investment and increasing appetite from private equity sponsors in pre-revenue stages.

Navigating the ever-changing market reality requires responding to growing competition whilst managing cost pressures all while trying to achieve sustainable growth. Get well-rounded advice across 46 jurisdictions from a life sciences transactions team with a keen view of the transactional landscape, industry trends and regulatory outlook.

Explore more below.

Collaborations and Licensing

expand accordion
  • Complex multinational collaborations
  • Joint ventures
  • Commercialization agreements
  • Co-promotion agreements
  • Research and development agreements
  • Evaluation and option agreements

M&A

expand accordion
  • Product acquisitions and divestitures
  • Company sales and acquisitions
  • Business unit spinoffs
  • Post-acquisition integration

Financings

expand accordion
  • Equity financing
  • Royalty monetization
  • Development funding agreements

Operational Agreements

expand accordion
  • Manufacturing and supply agreements
  • Distribution agreements
  • Services agreements
  • University and other nonprofit agreements
Insight | Handbook
Intellectual Property Insight
We approach IP management as a strategic issue and have developed the people, processes and technologies to serve as a one-stop shop for protecting the IP assets of global businesses.
Insight | Handbook
Guide to IPOs for Biotech and Pharma Companies
Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.
Insight | Podcast
The Health Pod
The Health Pod, Baker McKenzie's industry podcast series, highlights sector-specific issues and trends that affect healthcare and life sciences companies.
Insight | Thought Leadership
Data PULSE
Our Data PULSE platform helps you navigate the complex landscape of data, regulatory and IP protection concerns at each stage of the medical product life cycle.
Insight | Recorded Webinar
Healthcare & Life Sciences Supply Chain Series
The Supply Chain Series focuses on the trends, issues and opportunities along each stage of supply chain life cycle for healthcare and life sciences companies.
Insight | Recorded Webinar
Past Healthcare & Life Sciences Webinars
Learn more about the hot topics in the healthcare and life sciences industries.
View All Insight
News | Deal Announcement
Baker McKenzie Advises Incyte in Its AI-focused Research Collaboration with Genesis Therapeutics
The partnership offers Incyte the opportunity to leverage GEMS to accelerate the advancement of critical treatments for patients with severe diseases.
News | Deal Announcement
Baker McKenzie Advises Baxter in USD 3.8 Billion Divestiture of Vantive Kidney Care Segment to Carlyle
The deal represents a key milestone in Baxter’s ongoing business transformation, enabling heightened strategic clarity, operational efficiency and innovation.
News | Press Coverage
Singapore taps Vietnam for M&A/ investment opportunities; healthcare, real estate and construction sectors are key focus
M&A partner Seck Yee Chung shares his views about the future outlook of Singapore M&A deals in Vietnam.
News | Press Coverage
Alan Zoccolillo speaks to Mergermarket / Ion Analytics about deal activity in the North America healthcare sector
Alan Zoccolillo, discussed with Mergermarket/Ion Analytics the current trends driving the market and the near-term outlook for M&A activity in the sector.
News | Press Coverage
What the future holds for Biotech IPOs
Capital Markets Partners Adam Farlow and Sheng Chen shared their insights with BioSpectrum Asia. 
News | Case Announcement
Baker McKenzie represented Genomma Lab Internacional in the divestiture of its stake in Marzam
Leading global law firm Baker McKenzie announced today that the New York office represented Genomma Lab Internacional ("Genomma") in connection with the divestment of its stake in Mexican ...
News | Awards & Recognition
Baker McKenzie Partner Aarthi Belani Recognized Among Silicon Valley Business Journal's 2024 Women of Influence
Partner Aarthi Belani has been named to Silicon Valley Business Journal's prestigious 2024 Women of Influence list. 
News | Deal Announcement
Baker McKenzie advises Idorsia on entering into significant global research and development collaboration agreements
Under the agreements Viatris will receive exclusive worldwide development and commercialization rights for two Phase 3 assets.
News | Deal Announcement
Baker McKenzie Client Takeda Enters Worldwide License and Collaboration Agreement for Rusfertide
Rusfertide is currently in trial, VERIFY, for the treatment of Polycythemia Vera, a rare chronic blood disorder. 
View All News

Key Resources

FT Big Deal Series: The Healthtech Sector’s Spectacular Surge in SPACs and de-SPACS

A three minute video discussing how the pandemic triggered a significant rise in SPAC investments in the healthtech sector.


Flares of different colored light against a black background

Guide to IPOs for Biotech and Pharma Companies

Biotech and pharma companies undertaking capital raisings can approach the world’s capital markets in various ways.


The Health Pod

Baker McKenzie's industry podcast series that highlights sector-specific issues and trends that affect healthcare & life sciences companies.
Healthcare and Life Sciences video still

About Us

Learn about our Global Healthcare & Life Sciences Industry Group in five minutes.


How We Can Help

Key Contacts